Gut-brain axis insights: why the microbiota holds therapeutic potential for neuro-developmental disorders
Posted 17th April 2020 by Liv Sewell
Evidence is emerging that there are important connections between the gut microbiome and neurodevelopmental disorders. In a guest post for World Autism Awareness Month this April, Chris Kenji Beer reviews recent discoveries.
Posted 15th April 2020 by Joshua Sewell
Antibiotics consumption is increasing worldwide, yet these therapies not only destroy pathogens but also damage our vital intestinal flora.
Posted 8th April 2020 by Joshua Sewell
Hyperphagia is a common underlying cause of overweight and obesity. However, the dieting approaches towards weight loss are usually ineffective due to a persistent increase in appetite. Most of the current products in weight management are based on the principle of sugar/fat blockers and binders which has proven to be rather short-term solution.
Posted 6th April 2020 by Joshua Sewell
In 2017 Lisa and Alanna MacFarlane started The Gut Stuff to bring gut health science and nutritional information together for the millennial generation. We spoke to Lisa about educating consumers and marketing products in gut health.
Posted 1st April 2020 by Joshua Sewell
Probiotics have been recommended for many conditions during the past century, ranging from long-term immunomodulatory effects to proven benefits in the management of chronic diseases. There is an increased availability of commercial products containing probiotic strains. Do all of them indeed provide health benefits for their consumers? I am convinced they don’t.
Posted 30th March 2020 by Joshua Sewell
In the last decade, research has well established (relatively speaking) the impact of gut microbiota on host physiology and behaviour. We know that the gut and the brain communicate bidirectionally. The gut-brain axis includes nerval, endocrine and immunologic pathways. What is less well established is whether alterations in gut microbial composition can affect brain structure and function in neurodevelopmental disorders.
Posted 27th March 2020 by Joshua Sewell
This article is republished with kind permission from BioVox.
Augustine Therapeutics is one of VIB’s latest spinoffs, developing a first-in-class drug for Charcot-Marie-Tooth disease. The company recently announced a seed-funding round of €4.2 million, led by V-Bio Ventures. We spoke to several of the key persons in Augustine about how the startup is tackling the “Valley of Death”: the no-man’s-land between academia and industry where many potential therapies often fail.
Posted 23rd March 2020 by Liv Sewell
Both transplant outcomes and lab methods have stagnated over the last 40 years. Ishita Moghe and Professor Kim Solez comment upon the rapidly changing landscape of medical research and the potential of digital pathology for transforming patient outcomes.